Table 4
Group 2 (ADX10059 250 mg tds): number and total duration of reflux episodes and clinical symptoms
| Efficacy variable | ADX10059 250 mg tds, (n = 11) | Placebo tds, (n = 11) | p Value |
| Mean (SD) number reflux episodes (pH<4) in 24 h | 20.5 (19.4) | 32.7 (20.3) | NS |
| Mean (SD) total duration of reflux episodes (pH<4) in 24 h (min) | 39.9 (38.7) | 86 (72.2) | 0.0132 |
| Mean (SD) number nocturnal reflux episodes (pH<4) | 6.4 (9.9) | 13.6 (12.3) | NS |
| Mean (SD) total duration of reflux episodes (pH<4) nocturnal period (min) | 16.4 (29) | 48.7 (54) | 0.0021 |
| Mean (SD) number of symptomatic episodes | 1.9 (3.8) | 7.0 (13.8) | 0.031 |
| Mean (SD) duration of symptomatic episodes (min) | 5.2 (12.6) | 13.9 (20.1) | 0.031 |
-
tds, three times daily.
